Indian banks need USD 7 billion more cap: Fitch

Indian banks need USD 7 billion more cap: Fitch

In its 2020 Outlook for 'Asia-Pacific Emerging Market Banks', the rating agency maintained a negative outlook on Indian banks

AgenciesUpdated: Wednesday, December 04, 2019, 08:11 AM IST
article-image

New Delhi: Indian banks need an additional $7 billion (Rs 50,000 crore) equity by 2020-21 to support loan growth and cover for bad loans, Fitch Ratings said, adding a slowing economy could exacerbate asset-quality tension for a sector grappling with weak recoveries and ageing provisions.

In its 2020 Outlook for 'Asia-Pacific Emerging Market Banks', the rating agency maintained a negative outlook on Indian banks, based on its expectations of continued weak performance despite trends showing this could be past the trough, and ongoing capital requirements.

"Non-bank stress coupled with rising macro headwinds pose further challenges for asset quality, particularly at state banks which continue to experience capital constraints, delays in bad-loan recoveries, and poor earnings. More capital is needed to insulate the banks' weak balance sheets and to sustain loan growth," it said.

Fitch said the rating outlook for most Indian banks mirrors the stable outlook on India's sovereign rating.

RECENT STORIES

Trump Admin Scraps H-1B Lottery, Prioritizes High-Skilled, High-Paid Workers To Protect US Jobs

Trump Admin Scraps H-1B Lottery, Prioritizes High-Skilled, High-Paid Workers To Protect US Jobs

Unacademy Tightens ESOP Rules For Ex-Staff, Shorter Exercise Window Sparks Criticism Amid Takeover...

Unacademy Tightens ESOP Rules For Ex-Staff, Shorter Exercise Window Sparks Criticism Amid Takeover...

Rupee Strengthens 12 Paise To 89.51 On RBI's ₹3 Lakh Crore Liquidity Boost, Weaker Dollar

Rupee Strengthens 12 Paise To 89.51 On RBI's ₹3 Lakh Crore Liquidity Boost, Weaker Dollar

Sensex, Nifty Edge Higher Amid Positive Global Cues; Midcaps, Smallcaps Outperform

Sensex, Nifty Edge Higher Amid Positive Global Cues; Midcaps, Smallcaps Outperform

Biocon Out-Licenses Diabetes Drug To Ajanta Pharma For Marketing In 23 Countries

Biocon Out-Licenses Diabetes Drug To Ajanta Pharma For Marketing In 23 Countries